Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
|
AML
|
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
|
AML
|
CLAG Resistant: C4 – Case Studies
|
CLAG Resistant: C4 – Case Studies
|
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
|
AML
|
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
|
AML
|
venetoclax + midostaurin Sensitive: C4 – Case Studies
|
venetoclax + midostaurin Sensitive: C4 – Case Studies
|
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
|
AML
|
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
|
AML
|
IA Resistant: C4 – Case Studies
|
IA Resistant: C4 – Case Studies
|
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
|
AML
|
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
|
AML
|
venetoclax Resistant: C4 – Case Studies
|
venetoclax Resistant: C4 – Case Studies
|